Hyphens Pharma International (SGX:1J5) ROCE %: 17.49% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SGX:1J5 Hyphens Pharma International Ltd SGX:1J5
82 GF Score
Price S$0.36
GF Value S$0.31
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Hyphens Pharma International ROCE %?

Hyphens Pharma International SGX:1J5 -2.70% 82 ROCE % is 17.49% as of Jun. 2026. GuruFocus rates SGX:1J5 with a GF Score™ of 82/100 and a GF Value™ of S$0.31 (Modestly Overvalued). The stock has 7 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Hyphens Pharma International's annualized ROCE % for the quarter that ended in Jun. 2026 was 17.49%.

Hyphens Pharma International  (SGX:1J5) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Hyphens Pharma International ROCE % Related Terms

Hyphens Pharma International ROCE % Historical Data

* Premium members only.

The historical data trend for Hyphens Pharma International's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hyphens Pharma International ROCE % Chart

Hyphens Pharma International Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15.50 22.18 14.86 18.08 11.10

Hyphens Pharma International Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.03 15.43 8.61 14.74 17.49
SGX:1J5
82GF Score
Hyphens Pharma International Ltd SGX:1J5
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hyphens Pharma International ROCE % Calculation

Hyphens Pharma International's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=8.582/( ( (135.75 - 57.687) + (123.595 - 47.071) )/ 2 )
=8.582/( (78.063+76.524)/ 2 )
=8.582/77.2935
=11.10 %

Hyphens Pharma International's ROCE % of for the quarter that ended in Jun. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Jun. 2026 )  (Q: Dec. 2025 )(Q: Jun. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Jun. 2026 )  (Q: Dec. 2025 )(Q: Jun. 2026 )
=13.036/( ( (123.595 - 47.071) + (121.648 - 49.123) )/ 2 )
=13.036/( ( 76.524 + 72.525 )/ 2 )
=13.036/74.5245
=17.49 %

(1) Note: The EBIT data used here is two times the semi-annual (Jun. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 17.49% mean?
Hyphens Pharma International (SGX:1J5) has a ROCE % of 17.49% as of Jun. 2026.
Is Hyphens Pharma International's ROCE % too high?
Hyphens Pharma International's current ROCE % is 17.49%. The Medical Distribution industry median ROCE % is 8.83. Hyphens Pharma International's value of 17.49% is 98.2% above this industry median. Overall, Hyphens Pharma International has a GF Score™ of 82/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hyphens Pharma International's ROCE % compare to MCK and COR?
Hyphens Pharma International's ROCE % of 17.49% can be compared against companies in the Medical Distribution industry. The industry median ROCE % is 8.83. Hyphens Pharma International's value of 17.49% is 98.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Distribution company?
The median ROCE % among Medical Distribution companies is 8.83, based on 122 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hyphens Pharma International's current ROCE % of 17.49% is 98.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Distribution industry, the median ROCE % is 8.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hyphens Pharma International's current ROCE % is 17.49%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hyphens Pharma International stock overvalued right now?
Based on GuruFocus' analysis, Hyphens Pharma International (SGX:1J5) is currently considered Modestly Overvalued. The stock's GF Value™ is S$0.31, compared to a current price of S$0.36 — trading 16.1% above its estimated fair value. The current ROCE % is 17.49% and 98.2% above the Medical Distribution industry median of 8.83. Hyphens Pharma International's overall GF Score™ is 82/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Hyphens Pharma International (SGX:1J5), the current ROCE % is 17.49% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hyphens Pharma International (SGX:1J5) Overvalued in 2026?

Based on GuruFocus' analysis, Hyphens Pharma International stock appears to be overvalued. The current stock price of S$0.36 is trading 16.1% above its estimated GF Value™ of S$0.31. GuruFocus considers Hyphens Pharma International to be Modestly Overvalued.

Key valuation signals for SGX:1J5:

  • ROCE %: 17.49%
  • GF Value™: S$0.31 vs. price of S$0.36 (16.1% above fair value)
  • GF Score™: 82/100 with 7 warning signs
  • Industry Position: 98.2% above the Medical Distribution median

No single metric tells the full story. See the SGX:1J5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Hyphens Pharma International Business Description

Address 16 Tai Seng Street, Level 4, Singapore, SGP, 534138
Hyphens Pharma International Ltd is a pharmaceutical company. Its segments include the Pharmaceutical and Medical Aesthetics segment; Proprietary Brands segment; and Digital Platform and E-Pharmacy segment. The Pharmaceutical and Medical Aesthetics segment engages in the business of marketing and selling a range of pharmaceutical and medical aesthetics products with exclusivity in the relevant ASEAN countries. The Proprietary Brands segment develops, markets, and sells dermatological, pharmaceuticals and health supplement products. The Digital Platform and E-Pharmacy segment is a digital platform servicing procurement needs of healthcare professionals, healthcare institutions, and retail pharmacies, mainly in Singapore.
82GF Score

Get the complete analysis for SGX:1J5

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

S$0.36
Price
S$0.31
GF Value